Search research articles
Contact Us
Filters
Showing results (41-50 of 142) with videos related to
Page
of 15
Sort By:
Endocrine Journal
|
January 23, 2013
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu, Akira Teramoto, Naomi Hizuka, et al.
JCEM Case Reports
|
May 20, 2026
Histopathological evidence of osilodrostat-induced regression of a cortisol-producing adrenocortical adenoma
Maki Kanzawa, Takeshi Maeda, Yoshio Ohta, et al.
The Journal of Biological Chemistry
|
November 26, 2004
Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD
Junko Naito, Hiroshi Kaji, Hideaki Sowa, et al.
The Journal of Endocrinology
|
April 9, 2005
Dexamethasone suppresses Smad3 pathway in osteoblastic cells
Mei-Fway Iu, Hiroshi Kaji, Hideaki Sowa, et al.
The Journal of Biological Chemistry
|
October 1, 2003
Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts
Hideaki Sowa, Hiroshi Kaji, Mei Fway Iu, et al.
Journal of Bone and Mineral Metabolism
|
November 2, 2005
Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells
Mei-Fway Iu, Hiroshi Kaji, Junko Naito, et al.
Endocrine Journal
|
June 26, 2002
Plasma lipids and osteoporosis in postmenopausal women
Toru Yamaguchi, Toshitsugu Sugimoto, Shozo Yano, et al.
American Journal of Nephrology
|
August 10, 2002
Risk factors for hip fracture in hemodialysis patients
Hiroshi Kaji, Mizune Suzuki, Shozo Yano, et al.
Endocrine Journal
|
September 27, 2006
Growth hormone (GH) effects on central fat accumulation in adult Japanese GH deficient patients: 6-month fixed-dose effects persist during second 6-month individualized-dose phase
Kazuo Chihara, Akira Shimatsu, Yuzuru Kato, et al.
Endocrine Journal
|
September 2, 2006
Low-dose growth hormone treatment (0.175 mg/kg/week) for short stature in patients with Turner Syndrome: data from KIGS Japan
Yoshiya Ito, Kenji Fujieda, Toshiaki Tanaka, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 142) with videos related to
Sort By:
Page
of 15
Endocrine Journal
|
January 23, 2013
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu, Akira Teramoto, Naomi Hizuka, et al.
JCEM Case Reports
|
May 20, 2026
Histopathological evidence of osilodrostat-induced regression of a cortisol-producing adrenocortical adenoma
Maki Kanzawa, Takeshi Maeda, Yoshio Ohta, et al.
The Journal of Biological Chemistry
|
November 26, 2004
Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD
Junko Naito, Hiroshi Kaji, Hideaki Sowa, et al.
The Journal of Endocrinology
|
April 9, 2005
Dexamethasone suppresses Smad3 pathway in osteoblastic cells
Mei-Fway Iu, Hiroshi Kaji, Hideaki Sowa, et al.
The Journal of Biological Chemistry
|
October 1, 2003
Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts
Hideaki Sowa, Hiroshi Kaji, Mei Fway Iu, et al.
Journal of Bone and Mineral Metabolism
|
November 2, 2005
Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells
Mei-Fway Iu, Hiroshi Kaji, Junko Naito, et al.
Endocrine Journal
|
June 26, 2002
Plasma lipids and osteoporosis in postmenopausal women
Toru Yamaguchi, Toshitsugu Sugimoto, Shozo Yano, et al.
American Journal of Nephrology
|
August 10, 2002
Risk factors for hip fracture in hemodialysis patients
Hiroshi Kaji, Mizune Suzuki, Shozo Yano, et al.
Endocrine Journal
|
September 27, 2006
Growth hormone (GH) effects on central fat accumulation in adult Japanese GH deficient patients: 6-month fixed-dose effects persist during second 6-month individualized-dose phase
Kazuo Chihara, Akira Shimatsu, Yuzuru Kato, et al.
Endocrine Journal
|
September 2, 2006
Low-dose growth hormone treatment (0.175 mg/kg/week) for short stature in patients with Turner Syndrome: data from KIGS Japan
Yoshiya Ito, Kenji Fujieda, Toshiaki Tanaka, et al.
Page
of 15